1887

Abstract

There is a need for improvement of the commonly used adenovirus vectors based on serotype 5. This study was performed on three adenovirus serotypes with a CAR-binding motif (Ad4p, Ad5p and Ad17p) and three non-CAR-binding serotypes (Ad11p, Ad16p and Ad21p). The capacity of these alternative adenovirus vector candidates to deliver DNA into low-passage glioma cell lines from seven different donors was evaluated. The non-CAR-binding serotype Ad16p was the most efficient serotype with regard to import of its DNA, as well as initiation of hexon protein expression. Ad16p established hexon expression in 60–80 % of the cell population in gliomas from all donors tested. The other non-CAR-binding serotypes, Ad11p and Ad21p, showed hexon expression in 25–60 and 40–80 % of cells, respectively. The corresponding figure for the best CAR-binding serotype, Ad5p, was only 25–65 %, indicating greater variability between cells from different donors than serotype Ad16p had. The other CAR-binding serotypes, Ad4p and Ad17p, were refractory to some of the gliomas, giving a maximum of only 45 and 40 % hexon expression, respectively, in the most permissive cells. Interestingly, the transduction capacity of the CAR-binding serotypes was not correlated to the level of CAR expression on the cells.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80084-0
2004-09-01
2020-09-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/9/vir852627.html?itemId=/content/journal/jgv/10.1099/vir.0.80084-0&mimeType=html&fmt=ahah

References

  1. Albinsson B., Kidd A. H. 1999; Adenovirus type 41 lacks an RGD α v-integrin binding motif on the penton base and undergoes delayed uptake in A549 cells. Virus Res 64:125–136 [CrossRef]
    [Google Scholar]
  2. Arnberg N., Edlund K., Kidd A. H., Wadell G. 2000a; Adenovirus type 37 uses sialic acid as a cellular receptor. J Virol 74:42–48 [CrossRef]
    [Google Scholar]
  3. Arnberg N., Kidd A. H., Edlund K., Olfat F., Wadell G. 2000b; Initial interactions of subgenus D adenoviruses with A549 cellular receptors: sialic acid versus α v integrins. J Virol 74:7691–7693 [CrossRef]
    [Google Scholar]
  4. Asaoka K., Tada M., Sawamura Y., Ikeda J., Abe H. 2000; Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the coxsackievirus and adenovirus receptor. J Neurosurg 92:1002–1008 [CrossRef]
    [Google Scholar]
  5. Bergelson J. M., Cunningham J. A., Droguett G., Kurt-Jones E. A., Krithivas A., Hong J. S., Horwitz M. S., Crowell R. L., Finberg R. W. 1997; Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320–1323 [CrossRef]
    [Google Scholar]
  6. Bruning A., Kohler T., Quist S., Wang-Gohrke S., Moebus V. J., Kreienberg R., Runnebaum I. B. 2001; Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin β 3 subunit expression and increased by reconstitution of integrin α v β 3. Hum Gene Ther 12:391–399 [CrossRef]
    [Google Scholar]
  7. Buchholz C. J., Gerlier D., Hu A., Cathomen T., Liszewski M. K., Atkinson J. P., Cattaneo R. 1996; Selective expression of a subset of measles virus receptor-competent CD46 isoforms in human brain. Virology 217:349–355 [CrossRef]
    [Google Scholar]
  8. Carson S. D. 2001; Receptor for the group B coxsackieviruses and adenoviruses: CAR. Rev Med Virol 11:219–226 [CrossRef]
    [Google Scholar]
  9. Chillon M., Bosch A., Zabner J., Law L., Armentano D., Welsh M. J., Davidson B. L. 1999; Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C. J Virol 73:2537–2540
    [Google Scholar]
  10. Chirmule N., Propert K., Magosin S., Qian Y., Qian R., Wilson J. 1999; Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6:1574–1583 [CrossRef]
    [Google Scholar]
  11. Cichon G., Boeckh-Herwig S., Schmidt H. H., Wehnes E., Muller T., Pring-Akerblom P., Burger R. 2001; Complement activation by recombinant adenoviruses. Gene Ther 8:1794–1800 [CrossRef]
    [Google Scholar]
  12. Cohen C. J., Shieh J. T., Pickles R. J., Okegawa T., Hsieh J. T., Bergelson J. M. 2001; The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci U S A 98:15191–15196 [CrossRef]
    [Google Scholar]
  13. Dechecchi M. C., Melotti P., Bonizzato A., Santacatterina M., Chilosi M., Cabrini G. 2001; Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 75:8772–8780 [CrossRef]
    [Google Scholar]
  14. Fishelson Z., Donin N., Zell S., Schultz S., Kirschfink M. 2003; Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40:109–123 [CrossRef]
    [Google Scholar]
  15. Fisher K. D., Stallwood Y., Green N. K., Ulbrich K., Mautner V., Seymour L. W. 2001; Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 8:341–348 [CrossRef]
    [Google Scholar]
  16. Fox J. P., Hall C. E. 1980 In Viruses in Families , p. 318 Littleton, MA: PSG Publishing;
    [Google Scholar]
  17. Fuxe J., Liu L., Malin S., Philipson L., Collins V. P., Pettersson R. F. 2003; Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. Int J Cancer 103:723–729 [CrossRef]
    [Google Scholar]
  18. Gaggar A., Shayakhmetov D. M., Lieber A. 2003; CD46 is a cellular receptor for group B adenoviruses. Nat Med 9:1408–1412 [CrossRef]
    [Google Scholar]
  19. Greber U. F., Suomalainen M., Stidwill R. P., Boucke K., Ebersold M. W., Helenius A. 1997; The role of the nuclear pore complex in adenovirus DNA entry. EMBO J 16:5998–6007 [CrossRef]
    [Google Scholar]
  20. Hong S. S., Karayan L., Tournier J., Curiel D. T., Boulanger P. A. 1997; Adenovirus type 5 fiber knob binds to MHC class I α 2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J 16:2294–2306 [CrossRef]
    [Google Scholar]
  21. Ilan Y., Sauter B., Chowdhury N. R. 7 other authors 1998; Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology 27:1368–1376 [CrossRef]
    [Google Scholar]
  22. Kim M., Sumerel L. A., Belousova N., Lyons G. R., Carey D. E., Krasnykh V., Douglas J. T. 2003; The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells. Br J Cancer 88:1411–1416 [CrossRef]
    [Google Scholar]
  23. Kremer E. J., Boutin S., Chillon M., Danos O. 2000; Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J Virol 74:505–512 [CrossRef]
    [Google Scholar]
  24. Mack C. A., Song W. R., Carpenter H. 10 other authors 1997; Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 8:99–109 [CrossRef]
    [Google Scholar]
  25. Magnusson M. K., Hong S. S., Henning P., Boulanger P., Lindholm L. 2002; Genetic retargeting of adenovirus vectors: functionality of targeting ligands and their influence on virus viability. J Gene Med 4:356–370 [CrossRef]
    [Google Scholar]
  26. McQuaid S., Cosby S. L. 2002; An immunohistochemical study of the distribution of the measles virus receptors, CD46 and SLAM, in normal human tissues and subacute sclerosing panencephalitis. Lab Invest 82:403–409 [CrossRef]
    [Google Scholar]
  27. Mei Y. F. 1996; In The molecular basis for different tropisms in closely related adenoviruses , p. 228. PhD thesis Umeå University; Umeå, Sweden:
  28. Mei Y. F., Lindman K., Wadell G. 1998; Two closely related adenovirus genome types with kidney or respiratory tract tropism differ in their binding to epithelial cells of various origins. Virology 240:254–266 [CrossRef]
    [Google Scholar]
  29. Miller C. R., Buchsbaum D. J., Reynolds P. N., Douglas J. T., Gillespie G. Y., Mayo M. S., Raben D., Curiel D. T. 1998; Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 58:5738–5748
    [Google Scholar]
  30. Morral N., O'Neal W., Rice K. 12 other authors 1999; Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci U S A 96:12816–12821 [CrossRef]
    [Google Scholar]
  31. Nakamura T., Sato K., Hamada H. 2003; Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. J Virol 77:2512–2521 [CrossRef]
    [Google Scholar]
  32. Nicklin S. A., Von Seggern D. J., Work L. M., Pek D. C., Dominiczak A. F., Nemerow G. R., Baker A. H. 2001; Ablating adenovirus type 5 fiber-CAR-binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther 4:534–542 [CrossRef]
    [Google Scholar]
  33. Okegawa T., Pong R. C., Li Y., Bergelson J. M., Sagalowsky A. I., Hsieh J. T. 2001; The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res 61:6592–6600
    [Google Scholar]
  34. Olive M., Eisenlohr L., Flomenberg N., Hsu S., Flomenberg P. 2002; The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. Hum Gene Ther 13:1167–1178 [CrossRef]
    [Google Scholar]
  35. Rahman A., Tsai V., Goudreau A. 7 other authors 2001; Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systemic gene therapy. Mol Ther 3:768–778 [CrossRef]
    [Google Scholar]
  36. Roelvink P. W., Lizonova A., Lee J. G., Li Y., Bergelson J. M., Finberg R. W., Brough D. E., Kovesdi I., Wickham T. J. 1998; The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 72:7909–7915
    [Google Scholar]
  37. Schoggins J. W., Gall J. G., Falck-Pedersen E. 2003; Subgroup B and f fiber chimeras eliminate normal adenovirus type 5 vector transduction in vitro and in vivo . J Virol 77:1039–1048 [CrossRef]
    [Google Scholar]
  38. Segerman A., Arnberg N., Erikson A., Lindman K., Wadell G. 2003a; There are two different species B adenovirus receptors: sBAR, common to species B1 and B2 adenoviruses, and sB2AR, exclusively used by species B2 adenoviruses. J Virol 77:1157–1162 [CrossRef]
    [Google Scholar]
  39. Segerman A., Atkinson J. P., Marttila M., Dennerquist V., Wadell G., Arnberg N. 2003b; Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 77:9183–9191 [CrossRef]
    [Google Scholar]
  40. Seshidhar Reddy P., Ganesh S., Limbach M. P., Brann T., Pinkstaff A., Kaloss M., Kaleko M., Connelly S. 2003; Development of adenovirus serotype 35 as a gene transfer vector. Virology 311:384–393 [CrossRef]
    [Google Scholar]
  41. Shayakhmetov D. M., Papayannopoulou T., Stamatoyannopoulos G., Lieber A. 2000; Efficient gene transfer into human CD34+ cells by a retargeted adenovirus vector. J Virol 74:2567–2583 [CrossRef]
    [Google Scholar]
  42. Skog J., Mei Y. F., Wadell G. 2002; Human adenovirus serotypes 4p and 11p are efficiently expressed in cell lines of neural tumour origin. J Gen Virol 83:1299–1309
    [Google Scholar]
  43. Smith T. A., White B. D., Gardner J. M., Kaleko M., McClelland A. 1996; Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther 3:496–502
    [Google Scholar]
  44. Soudais C., Boutin S., Hong S. S., Chillon M., Danos O., Bergelson J. M., Boulanger P., Kremer E. J. 2000; Canine adenovirus type 2 attachment and internalization: coxsackievirus- adenovirus receptor, alternative receptors, and an RGD-independent pathway. J Virol 74:10639–10649 [CrossRef]
    [Google Scholar]
  45. Thomas C. E., Schiedner G., Kochanek S., Castro M. G., Lowenstein P. R. 2000; Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci U S A 97:7482–7487 [CrossRef]
    [Google Scholar]
  46. van Oostrum J., Burnett R. M. 1985; Molecular composition of the adenovirus type 2 virion. J Virol 56:439–448
    [Google Scholar]
  47. Vogels R., Zuijdgeest D., van Rijnsoever R. 20 other authors 2003; Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77:8263–8271 [CrossRef]
    [Google Scholar]
  48. Wadell G. 1984; Molecular epidemiology of human adenoviruses. Curr Top Microbiol Immunol 110:191–220
    [Google Scholar]
  49. Wang K., Guan T., Cheresh D. A., Nemerow G. R. 2000; Regulation of adenovirus membrane penetration by the cytoplasmic tail of integrin β 5. J Virol 74:2731–2739 [CrossRef]
    [Google Scholar]
  50. Wickham T. J., Mathias P., Cheresh D. A., Nemerow G. R. 1993; Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73:309–319 [CrossRef]
    [Google Scholar]
  51. Wu E., Pache L., Von Seggern D. J., Mullen T. M., Mikyas Y., Stewart P. L., Nemerow G. R. 2003; Flexibility of the adenovirus fiber is required for efficient receptor interaction. J Virol 77:7225–7235 [CrossRef]
    [Google Scholar]
  52. Youil R., Toner T. J., Su Q., Chen M., Tang A., Bett A. J., Casimiro D. 2002; Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther 13:311–320 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80084-0
Loading
/content/journal/jgv/10.1099/vir.0.80084-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error